[{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"}]

Find Clinical Drug Pipeline Developments & Deals for Strontium-89 Chloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic...

                          Product Name : Metastron

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          July 03, 2022

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Chengdu Syncor Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

                          Product Name : Metastron

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          December 07, 2021

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Clionix

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                          Product Name : Metastron

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          October 08, 2021

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : isoSolutions

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank